MoonLake Immunotherapeutics logo
MLTXMoonLake Immunotherapeutics
Trade MLTX now
MoonLake Immunotherapeutics primary media

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX) focuses on revolutionizing the treatment landscape for patients with immune-mediated diseases. This entails developing innovative therapies that can significantly improve quality of life and outcomes for those suffering from conditions like psoriasis, inflammatory bowel disease, and other chronic autoimmune conditions. MoonLake aims to harness the power of cutting-edge science and technology to create drugs that can effectively target and modulate the immune system, providing new hope for patients with limited treatment options. With a commitment to rigorous research and clinical development, MoonLake is steadfast in its mission to bring groundbreaking therapies from the lab bench to the bedside, striving to lead a new era in immunotherapy.

What is MLTX known for?

Snapshot

Public US
Ownership
2020
Year founded
53
Employees
Zug, Switzerland
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Switzerland

Products and/or services of MoonLake Immunotherapeutics

  • Development of sonelokimab for various inflammatory diseases, focusing on psoriasis, psoriatic arthritis, and ankylosing spondylitis.
  • Innovative treatments based on Nanobody technology targeting immune-mediated diseases.
  • Partnerships for research and development in dermatology and rheumatology.
  • Expansion of the Nanobody technology platform for broader therapeutic applications.
  • Customized clinical development programs for immune-mediated inflammatory conditions.
  • Pipeline development of next-generation biologics for autoimmune diseases.

MoonLake Immunotherapeutics executive team

  • Dr. Jorge Santos da Silva Ph.D.Co-Founder, CEO & Director
  • Dr. Kristian Reich M.D., Ph.D.Co-Founder & Chief Scientific Officer
  • Mr. Matthias BodenstedtChief Financial Officer
  • Mr. Oliver Daltrop Ph.D.Chief Operations Officer
  • Ms. Carla BretesDirector of Investor Relations & External Communications
  • Mr. Nicolas Mosimann Ph.D.General Counsel
  • Joana CortezSenior Director Legal & Compliance
  • Tino AnthamattenVice President of Marketing, Market Access & Pricing
  • Luciana MarquesDirector of HR, People & Culture
  • Ms. Nuala BrennanChief Clinical Development Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.